GlassScriptPhysician profile
Austin Mansfield
NPI 1568191088
$3,276.33
in general payments reported to CMS, 2019-2025
24 companies · $30.06 in 2025
The $30.06 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $277 · 2023: $901 · 2024: $2,067 · 2025: $30.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,884 · Consulting Fee: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,884.04 |
| Consulting Fee | $115.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $641.00 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Janssen Pharmaceuticals, INC | $373.68 | 2022-2024 | Spravato, Invega Sustenna |
| Abbvie INC. | $283.02 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $279.17 | 2022-2024 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $274.27 | 2022-2024 | Caplyta |
| Axsome Therapeutics, INC. | $265.31 | 2023-2024 | Auvelity, Sunosi |
| Indivior INC. | $178.60 | 2022-2024 | Sublocade, Perseris |
| Alkermes, INC. | $116.84 | 2023-2024 | Aristada, Lybalvi |
| Janssen Scientific Affairs, LLC | $115.00 | 2024 | Spravato |
| Lundbeck LLC | $103.20 | 2023-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $97.36 | 2023-2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $93.80 | 2024 | |
| Braeburn INC. | $53.70 | 2024 | Brixadi |
| Biogen, INC. | $53.09 | 2024 | Zurzuvae |
| Vanda Pharmaceuticals INC. | $52.84 | 2023-2024 | Fanapt, Hetlioz |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $50.19 | 2023-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $42.21 | 2024 | |
| Supernus Pharmaceuticals, INC. | $39.24 | 2023 | Qelbree |
| Corium, LLC | $36.63 | 2023 | Azstarys |
| Tris Pharma INC | $35.65 | 2022-2023 | Dyanavel Xr |
| Nalu Medical, INC. | $28.96 | 2024 | Nalu Neurostimulation System |
| Tempus Ai, INC | $27.54 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.45 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.58 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Mansfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.